Immunomodulatory therapies are transforming modern medicine by enabling targeted immune responses for the treatment of cancer, autoimmune diseases, and infectious conditions.
This scientific journal explores how cytokine release assays (CRAs) play a crucial role in identifying immune activation risks during nonclinical safety assessments.
It examines the scientific principles, experimental approaches, and assay design considerations used to evaluate cytokine release in vitro, supporting safer development pathways for immunomodulatory therapies.
Read to discover:
- Why cytokine release evaluation is essential for derisking immunomodulatory drug development
- Key triggers and indicators that necessitate in vitro cytokine release testing during nonclinical studies
- Different CRA approaches, including PBMC assays and whole blood assays, used to assess immune activation
